CatalYm GmbH
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-31
RECRUITING4
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| GDFATHER NCT04725474 |
P1/2 | Active, not recruiting | Solid Tumor, Adult | 199 | 2028-04-30 (+59 mo) |
| Visugromab NCT07098988 |
P2 | Recruiting | Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor | 107 | 2029-03-31 |
| GDFATHERHCC01 NCT07219459 |
P2 | Recruiting | Unresectable or Metastatic Hepatocellular Carcinoma; Child-Pugh A Hepatocellular Carcinoma | 104 | 2029-09 |
| Visugromab RDE (recommended dose for expansion) NCT07246863 |
P2 | Recruiting | Metastatic Non-Squamous Non-Small Cell Lung Cancer; Adult Solid Tumor | 131 | 2029-10-01 |
| VINCIT NCT07112196 |
P2/3 | Recruiting | Cancer-associated Cachexia | 518 | 2029-12 |